|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-TripleA was detected in 1678 (65%) patients with T1D, 4 (9%) T2D, 3 (11%) MODY and in none (0%) of the patients with secondary diabetes.
|
21708156 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rate of progression from NFG to IFG was significantly greater in participants carrying the risk allele at MTNR1B (p = 1 × 10(-4)), nominally greater at GCK and SLC30A8 (p < 0.05) and nominally smaller at IGF2BP2 (p = 0.01) than the rate of progression from IFG to diabetes by the LRT.
|
22038522 |
2012 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoantibody-negative patients were retested at median diabetes duration of 3.2 yr (range 0.9-16.2) for autoantibodies (GAD, IA2, ZnT8), human leukocyte antigen (HLA) typing, non-fasting C-peptide, and sequencing of HNF4A, HNF1A, KCNJ11, and INS.
|
21518407 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Leptin (LEP), a protein that plays a fundamental role in the metabolism of energy reserves, and the solute carrier family 30 A8 zinc transporter (SLC30A8) have been consistently associated with diabetes.
|
28363002 |
2017 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Associations between ZnT8 antibody (ZnT8A), phenotype and the genetic variant rs13266634 in the SLC30A8 gene have primarily been studied in patients with young-onset diabetes.
|
23061550 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other outcomes are: (1) Any persistent confirmed beta-cell autoantibody (glutamic acid decarboxylase (GADA), IA-2A, autoantibodies to insulin (IAA) and zinc transporter 8 or tetraspanin 7), or diabetes, (2) Persistent confirmed IAA, (3) Persistent confirmed GADA and (4) Abnormal glucose tolerance or diabetes.
|
31256036 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Children, younger than 15 years of age (n = 723) who were newly diagnosed with diabetes, were analyzed for ZnT8A, other diabetes-associated autoantibodies, HLA DR-DQ alleles, and metabolic status, which was monitored by pH, plasma glucose, and occurrence of ketoacidosis at diagnosis and through follow-up of C-peptide concentrations, exogenous insulin dose, and glycosylated hemoglobin for 2 years after the diagnosis.
|
26519333 |
2016 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A rare variant association study has now established the direction of effect, surprisingly showing that loss-of-function mutations in SLC30A8 are protective against diabetes.
|
24675520 |
2014 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review, we summarize the structure, feature, functions, and polymorphisms of ZnT8 along with its association with diabetes and explore future study directions.
|
30936916 |
2019 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The C-terminal cytosolic domain of the human zinc transporter ZnT8 and its diabetes risk variant.
|
29430817 |
2018 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of ZnT8A were measured in 2,239 British type 1 diabetic individuals diagnosed before age 17 years, with a median duration of diabetes of 4 years.
|
22526605 |
2012 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we review the regulation and roles of Zn<sup>2+</sup> ions in islet cells, the mechanisms through which SLC30A8 variants might affect glucose homeostasis and diabetes risk, and the novel technologies including recombinant targeted zinc probes and knockout mice which have been developed to explore these questions.
|
27262257 |
2016 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The breakthrough discovery that the common polymorphism in zinc transporter <i>SLC30A8</i>/ZnT8 may increase susceptibility to type 2 diabetes provided novel insights into the role of zinc in diabetes.
|
29415457 |
2018 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Zinc supplementation appears to affect the early insulin response to glucose differentially by rs13266634 genotype and could be beneficial for diabetes prevention and/or treatment for some individuals based on SLC30A8 variation.
|
25348609 |
2015 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blood samples were obtained from 900 patients with age from 1 month to 25 years (median age 11.1 years) within 2 weeks of diabetes onset to test anti-islet autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma antigen (IA-2AA), the zinc transporter-8 (ZnT8AA), and islet-cell antibodies (ICA).
|
21138544 |
2011 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic and physiological studies suggest a role for the zinc transporter gene SLC30A8 in diabetes risk, possibly through effects on insulin-processing in beta cells.
|
21779873 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we characterize an emerging role of ZnT-8 in diabetes and discuss potential mechanisms of its involvement in the etiology of both forms of diabetes.
|
19655390 |
2009 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 97 subjects with diabetes onset before age 25, a random C-peptide ≥0.1 ng/mL, and negative for all diabetes autoantibodies (GADA, IA-2, ZnT8, and IAA) were enrolled, after excluding 21 subjects with secondary diabetes or refusal to participate.
|
26059258 |
2016 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Diabetes Autoimmunity Study in the Young (DAISY) followed prospectively for development of persistent IA (autoantibodies to insulin, GAD65, IA-2, or ZnT8 on at least two consecutive exams) and diabetes 1715 non-Hispanic white children at increased genetic risk for T1D.
|
22776074 |
2012 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 31 Somali children ≤19 yr were treated for type 1 diabetes (T1D) at the University of Minnesota Masonic Children's Hospital and Children's Hospitals and Clinics of Minnesota underwent analysis of human leukocyte antigen (HLA) alleles (n = 30) and diabetes autoantibodies [glutamic acid decarboxylase (GAD65), islet antigen 2 (IA-2), zinc transporter 8 (ZnT8); n = 31].
|
26854192 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present review, we summarize the literature about clinical aspects of ZnT8 in the pathogenesis of diabetes, and suggest that ZnT8 might play a different role between type 1 diabetes mellitus and type 2 diabetes mellitus.
|
27181765 |
2016 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, Znt8 Arg-325 risk variant shows an enhanced inflammatory response upon LPS stimulation that might aggravate insulin resistance and the progression of diabetes cardiovascular complications.
|
30142362 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
It argues against ZnT8 autoimmunity arising from molecular mimicry and suggests a mechanistic link between the two major forms of diabetes.
|
18591387 |
2008 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-ab positive patients had higher titre and more frequent occurrence of multiple diabetes-related autoantibodies than ZnT8-ab negative patients.
|
30465779 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-ab are associated with more acute diabetes onset.
|
29327148 |
2018 |